Let's talk about biotech. what's up
investors and welcome back to the
channel today I want to talk about six
biotech companies that have huge upside
potential. Yes, in this short video I will
cover six of the best biotech stocks on
the market right now. Each of these is
backed up by huge analysts price targets
of up to 10x. I will look at the latest
developments for each company and the
upcoming catalyst that will drive these
stock prices in 2022. some of these
companies have expected catalysts as soon
as next week so stay to the end of the
video and don't miss out!
The big question is....
Are these good stocks to buy right now?
before we get into the video if you like
this content can I ask you to smash the
like button, i'm aiming to get 300 likes
on this video help me achieve this goal
it literally costs you nothing but it
helps me out so much. subscribe to the
channel if you're new and hit the bell
notification so you never miss out on a
video that has the potential to make you
money.
I want to point out that i'm not a
financial advisor and this is not
financial advice now let's get into it
with the first stock on the list:
Citius pharmaceuticals nasdaq ticker:CTXR
#biotech stock
Citius is a late stage
biopharmaceutical company focused on the
development and commercialization of
critical care products with a pipeline
of anti-infectives
in cancer care oncology stem cell
therapy and unique prescription products.
The company is developing five
proprietary products comprising of
ion attack
for the treatment of patients with
persistent or recurrent
cutaneous t cell lymphoma
minoloc an antibiotic lock solution to
treat patients with
catheter related bloodstream infections
halolido a cordial steroid to provide
anti-inflammatory and aesthetic relief
from hemorrhoids
minor wrap a gel based wrap for
reduction of tissue expander infections
following breast reconstructive
surgeries
and the company is also working on a
novel (ctxr stock)
stem cell therapy for the treatment of
acute inflammatory respiratory disorders
including acute respiratory
distress syndrome or herds
for which there is currently no
fda approved treatments.
Citius has a series of upcoming
catalysts for 2022 as we can see here
Citius anticipates filing a bla for
iontech with the fda in the second half
of 2022 and has shown encouraging
top-line data from a phase 3 study
there is also upcoming trials for halo
lido and minolok too but
Is Citius pharmaceuticals a good investment?
analysts consider citius pharmaceuticals to be a strong buy!
(CTXR Stock)
three wall street analysts offering 12
month price targets with an average
price target of $6.67.
with a high forecast of 10 and a low
cost
and a low forecast of four this offers
significant upside from the current
price of just 103.
guys if you would like me to do a full
video on Citius pharmaceuticals
ticker ctxr
then comment this down below
next up is northwest biotherapeutics
this is an otc stock trading on the
otcqb ticker NWBO
#northwestbio
northwest biotherapeutics
is a clinical stage biotech company
focused on the development of
personalized cancer vaccines designed to
treat a broad range of solid tumor
cancers using a treatment to avoid the
side effects of chemotherapy drugs
northwest has a broad platform
technology dc vacs cell-based vaccines
the company's lead program is a 331
patient phase 3 trial of dc vax l for
newly diagnosed gbm which is the most
aggressive and lethal form of brain
cancer but the company has also
developed dc vax direct or inoperable
solid tumor cancers back in february
northwest began production of its first
dendritic cell
cancer vaccine for a compassionate use
patient at its production facility in
the uk the company anticipates that
phase 1a of the uk facility will have
the capacity to produce cancer vaccines
for between 450 and 500 patients per
year
and then just this week northwest
announced an upcoming presentation will
be made on may 10th by dr linda lao at
the frontiers of cancer immunotherapy
conference of the new york academy of
sciences but
Is northwest biotherapeutics a good stock to buy right now?
(OTCQB:NWBO)
because this company trades on the otc
there is no reliable analyst price
targets but this is beginning to gather
a lot of investor interest over the past
five weeks this stock has been on an
incredible run from just 70 cents on the
5th of april
up to its current price of 186. if you
want to hear more about this stock then
comment northwest down below.
Kempharm.
this is the nasdaq listed company with
the ticker kmph. Kempharm is a speciality
pharmaceutical company focused on the
discovery and development of proprietary
pro drugs to treat serious medical
conditions through its proprietary lat
technology
they use this technology to generate
improved pro-drug versions of
fda-approved drugs as well as to
generate pro-drug versions of existing
compounds that may have applications for
new disease indications
Kempharm's project product pipeline is
focused on the high need areas of adhd
and stimulant use disorder
in their pipeline Kempharm currently
have two approved product products
and its product candidates are focused
around kp 1077 and kp 879 which are
being developed to treat sleep disorders
and stimulant use disorder
last month Kempharm started their early
stage cardiovascular safety study data
from the study is expected in the third
quarter of 2022 and the company is
planning to initiate two mid-stage
studies in 2022 to evaluate
ap107 as treatment for hyperinsomnia and
narcolepsy and yesterday Kempharm
announced the submission
of investigational new drug application
for the phase 2 trial of k of kp 1077 in
hyperinsomnia.
So, Is Kempharm a good stock to buy now?
Kempharm is currently trading near its
52-week low right now but analysts rate
this stock as a boy with a price target
of $11.
but very interestingly about this
company the current market cap has now
dropped equal to shareholders equity
himfam have no debt and over 110 million
dollars in cash with a with a very low
cash burn
the next earnings report is due on may
12th and I expect to see more revenue
growth if you would like to see more
about this stock then comment Kempharm Stock.
down below. ($KMPH)
180 life sciences is nasdaq listed with
the ticker atnf
180 life sciences is a clinical stage
biotechnology company focused on the
development of novel drugs to treat
inflammatory diseases fibrosis and pain
this company went public in november
2020 through a merger with a spak and
had raised over 100 million dollars
the company's primary platform is a
novel program to treat fibrosis using
anti-tnf hence the ticker atnf but
they're also developing
synthetic cbd analogs
and then there is the a7 program where
180 life sciences are developing a
treatment for
ulcerative colitis and ex-smokers so
here we can see an overview of these
three programs and the technologies the
targeted diseases competitive advantages
the stage they're at and the
intellectual property involved
looking at the pipeline we can see
that these are heading into phase three
for several indications in the very near
future
and over the past week 180 have
announced final results from its phase
2b study in patients with fibrosis of
the hands the positive data results were
published in the lancet rheumatology but
Is 180 life sciences a good stock to buy?
right now there was only one wall street
analyst covering this stock and that is
maxim group and they have rated 180 as a
strong boy and given a prize target of
$11
do you want to hear more about this
company
then drop a comment down below 180 life
sciences
guys if you've watched this far into the
video and you enjoy the content please
smash the like button and follow me on
twitter so you don't miss out on any
alerts or stock updates such as my
recent alert a red box at only 3.37
which reached as high as 10 earlier this
week next up is oxygen this company is
traded on the nasdaq with the ticker ocg
in oxygen is focused on discovering
developing and commercializing novel
gene therapies biologicals and vaccines
that improve health and offer hope for
people and global communities
one of oxygen's main focus areas is
finding
innovation
that will make hard-to-treat blindness
diseases a thing of the past
using innovation to take science in new
directions in service of patients their
breakthrough modifier gene therapy
platform has the potential to treat
multiple diseases with one drug and they
are advancing research in other
therapeutic areas to offer new options
for people with unmet medical needs
oxygen have a number of programs at
various stages in their pipeline their
leading drug is kovaxin but they also
have
ocu 400 ocu-410
and ocu-200 which are at various stages
of testing so far this year oxygen stock
has dropped over 50 percent which
represents really good buying
opportunity right now one of the reasons
for this sharp drop is that the fda
placed a clinical hold on kovacsen
but today oxygen released their latest
quarterly report where they missed
analyst estimates and so the share price
has dropped further but they also
released a business update
in this they are showing that they are
in discussions with the fda to resume
phase two and three as well as
discussions with canada held and
expansion into mexico in april
on top of this the first patient first
dosed for ocu 400 clinical trial and
growing the organization by nearly 20
further employees during the first
quarter so with the current drop is
oxygen a stock to buy or is oxygen a
good investment the overall analyst
price target consensus for oxygen is 825
with four wall street analysts giving
price targets as low as four and as high
as 15 with the consensus rating being a
moderate buy
comment oxygen down below if you want to
hear more about this company
processor pharmaceuticals is a clinical
stage biopharmaceutical company traded
on the nasdaq with the ticker pcsa this
company is focused on the development of
drug products that are intended to
provide treatment and improve quality of
life of patients who have unmet medical
needs or who have no alternative
treatments their strategy includes
identifying drugs that have potential
efficacy in patients with unmet medical
needs
identifying drug products that have been
developed or approved for other
indications but can be repurposed to
treat patients who have unmet medical
needs and identifying drugs that can
quickly be developed such that within
two to four years critical value can be
added
to meet clinical milestones while
advancing the drug closer to
commercialization processor have a
number of drugs in their pipeline that
offer multi-billion dollar opportunities
the most advanced is pcs 499 and four
other licensed drugs at various
milestone stages three of these are
cleared by the fda for clinical trials
so this is great to see
processor have many key milestones
coming up in the second half of 2022
but is processor a good stock to buy
right now looking at market beat we can
see that the general analyst rating
consensus is a buy while the analyst
price target consensus is 22
which offers an incredible 9x upside
from the current price guys if you would
like to know more about processor
and for me to do a full video on this
company then drop a comment down below
so what did you think of these biotech
stocks are you buying holding or selling
any of these
drop a comment and let me know what you
were doing and what price targets you
have and if you agree or disagree with
the wall street analysts regarding any
of these stocks I would greatly
appreciate if you could smash the like
button and hit the subscribe button if
you're new to the channel or follow me
on twitter and i'll catch you in the
next update video